2019 Post-ESMO Report - ResearchAndMarkets.com

The "2019 Post-ESMO Report" has been added to ResearchAndMarkets.com's offering.

• The Annual European Society for Medical Oncology (ESMO) 2019 Congress was held in Barcelona, Spain from September 27 to October 1, 2019.
• Conference highlights included new data from PARP inhibitors in ovarian cancer, such as Zejula, Lynparza and veliparib, as well as a follow-up update for KRAS-targeted drug AMG 510 for colorectal cancer, and CDK4/6-inhibitors, Kisqali and Verzenio, for breast cancer.
• Key pipeline updates for more established drugs were highly featured including Keytruda for non-small lung cancer and Kisqali for breast cancer.
  

2019 Post-ESMO Report features summaries of a few key topics along with commentary from analysts on specific presentations. It also includes a compilation of all data events added in conjunction with the meeting.

Drug Abstracts Covered

Biliary Tract Cancer

• Pemigatinib for Biliary Tract Cancer (INCY, Phase III)
• Tibsovo for Biliary Tract Cancer (AGIO, Phase III)

Bladder Cancer

• Enfortumab Vedotin for Bladder Cancer (Astellas, BLA)
• Sacituzumab Govitecan for Bladder Cancer (IMMU, Phase II)
• Tecentriq for Bladder Cancer (RHHBY, Approved)

Breast Cancer

• G1T48 for Breast Cancer (G1 Therapeutics, Phase I)
• Keytruda for Breast Cancer (MRK, Phase III)
• Keytruda for Breast Cancer (MRK, Phase III)
• Kisquali for Breast Cancer (NVS, Approved)
• Trilaciclib for Breast Cancer (G1 Therapeutics, Phase II)
• Verzenio for Breast Cancer (LLY, Approved)

Colorectal Cancer

• AMG 510 for Colorectal Cancer (CRC) (AMGN, Phase I)
• Braftovi for Colorectal Cancer (CRC) (PFE, Phase III)
• Tucatinib for Colorectal Cancer (CRC) (PFE, Phase III)

Oesophagal Cancer

• Opdivo for Esophageal Cancer (BMY, Phase III)

Gastric Cancer

• Margetuximab for Gastric Cancer (MGNX, Phase II)

Head & Neck Cancer

• Debio 1143 for Head and Neck Cancer (Debiopharm, Phase II)
• Monalizumab for Head and Neck Cancer (AZN, Phase II)
• Hepatocellular (Liver) Cancer (HCC) (Including Secondary Metastases)
• Opdivo for Hepatocellular (Liver) Cancer (HCC) (Including Secondary Metastases) (BMY, Approved)
• Tecentriq for Hepatocellular (Liver) Cancer (HCC) (Including Secondary Metastases) (RHHBY, Phase III)

Non-Small Cell Lung Cancer (NSCLC)

• AMG 510 for Non-Small Cell Lung Cancer (NSCLC) (AMGN, Phase I)
• Opdivo for Non-Small Cell Lung Cancer (NSCLC) (BMY, Approved)
• Tagrisso for Non-Small Cell Lung Cancer (NSCLC) (AZN, Approved)
• Tecentriq for Non-Small Cell Lung Cancer (NSCLC) (RHHBY, Approved)

Ovarian Cancer

• AVB-500 for Ovarian Cancer (ARAV, Phase II)
• Lynparza for Ovarian Cancer (AZN, Approved)
• M6620 for Ovarian Cancer (MKGAY, Phase II)
• Mirvetuximab Soravtansine for Ovarian Cancer (IMGN, Phase III)
• Veliparib for Ovarian Cancer (ABBV, Phase III)
• Zejula for Ovarian Cancer (GSK, Approved)

Prostate Cancer

• Erleada for Prostate Cancer (JNJ, Approved)
• Lynparza for Prostate Cancer (AZN, Phase III)
• Rubraca for Prostate Cancer (CLVS, Phase III)
• SM-88 for Prostate Cancer (TYME, Phase II)
• Zejula for Prostate Cancer (GSK, Phase III)

Renal Cell Cancer (RCC)

• Mavorixafor for Renal Cell Cancer (RCC) (XFOR, Phase II)
• MK-6482 for Renal Cell Cancer (RCC) (MRK, Phase II)
• Tivopath (Oncology) for Renal Cell Cancer (RCC) (AVEO, Phase III)

Solid Tumors

• ALRN-6924 for Solid Tumors (ALRN, Phase II)

Thyroid Cancer

• Selpercatinib for Thyroid Cancer (LLY, Phase II)

For more information about this report visit https://www.researchandmarkets.com/r/dsfm55

View source version on businesswire.com: https://www.businesswire.com/news/home/20191121005780/en/